This consensus document reviews the appropriate laboratory tests, patient selection, and timing for evaluating the anticoagulant effect of dabigatran, rivaroxaban, and apixaban.
At variance with vitamin K antagonists, the new oral anticoagulants(NOAs) can be prescribed at fixed dosage without adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper represents the consensus document of three Italian scientific societies dealing with laboratory issues in thrombosis and hemostasis. It is aimed at reviewing: 1) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available(i.e., dabigatran, rivaroxaban and apixaban); 2) the patients to be investigated; and 3) the timing of investigation.
Tripodi et al. (Wed,) conducted a review in Patients taking new oral anticoagulants. Laboratory testing for new oral anticoagulants (dabigatran, rivaroxaban, apixaban) was evaluated. This consensus document reviews the appropriate laboratory tests, patient selection, and timing for evaluating the anticoagulant effect of dabigatran, rivaroxaban, and apixaban.